Biotech startups that raised Series C in Europe
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Microbiotica | Cambridge | Series C | $47.9M | 2026-10-16 |
| Basecamp Research | London | Series C | $140.0M | 2026-09-23 |
| Automata | London | Series C | $45.0M | 2026-06-25 |
| ADCendo | Copenhagen | Series C | $75.0M | 2026-04-14 |
| Brainomix | Oxford | Series C | $6.5M | 2026-02-24 |
| Nuclera | Cambridge | Series C | $12.0M | 2026-01-13 |
| 4TEEN4 Pharmaceuticals | Hennigsdorf | Series C | $36.1M | 2025-11-13 |
| Tubulis | Munich | Series C | $400.6M | 2025-10-15 |
8 rows of the CSV in 5 of its 18 columns.
- The 111 biotech startups in Europe whose last round is Series C have raised $7.1B in total.
- 10 of them closed their most recent round in the last 12 months, $835.1M combined.
- The largest of those rounds is OMass Therapeutics' $310.0M Series C, dated October 2026.
- The most recent is Microbiotica's $47.9M Series C on 16 October 2026.
- KfW is an investor in 7 of them, more than any other fund.
- Health care is the most common other sector, with 93 companies (84%).
- 0% were founded in 2020 or later; the median founding year is 2010.
- The most common team size is 11 to 50 employees (57% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
26 of 111| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Microbiotica | Microbiotica develops live bacterial microbiome therapeutics and associated biomarkers. | Biotech | Cambridge, United Kingdom | Series C | $47.9M | 2026-10-16 | $130.7M | Seventure Partners, IP Group, Cambridge Innovation Capital +1 | 11 to 50 | 2016 |
| Basecamp Research | Basecamp Research is a biotechnology company that uses AI and biological data to develop therapeutics. | Artificial intelligence | London, United Kingdom | Series C | $140.0M | 2026-09-23 | $219.9M | True Ventures, redalpine, Hummingbird Ventures +1 | 51 to 100 | 2019 |
| Automata | Automata provides laboratory automation software and hardware to increase efficiency in scientific workflows. | Artificial intelligence | London, United Kingdom | Series C | $45.0M | 2026-06-25 | $144.8M | Octopus Ventures, Firstminute Capital, Hummingbird Ventures +1 | 101 to 250 | 2015 |
| ADCendo | ADCendo develops antibody-drug conjugates to target cancers with high unmet medical needs. | Biotech | Copenhagen, Denmark | Series C | $75.0M | 2026-04-14 | $324.6M | RA Capital Management, Novo Holdings, Gilde Healthcare +2 | 51 to 100 | 2017 |
| Brainomix | Brainomix creates AI-powered imaging biomarkers that support precision medicine treatment decisions. | Artificial intelligence | Oxford, United Kingdom | Series C | $6.5M | 2026-02-24 | $60.2M | Innovate UK, Parkwalk Advisors, Boehringer Ingelheim Venture Fund +1 | 51 to 100 | 2010 |
| Nuclera | Nuclera provides a protein prototyping system that makes proteins readily available to drug discovery researchers. | Biotech | Cambridge, United Kingdom | Series C | $12.0M | 2026-01-13 | $157.8M | Innovate UK, Verve Ventures, Amadeus Capital Partners +2 | 101 to 250 | 2013 |
| 4TEEN4 Pharmaceuticals | 4TEEN4 Pharmaceuticals develops therapies and biomarkers for diagnosing, predicting, and treating circulatory shock. | Biotech | Hennigsdorf, Germany | Series C | $36.1M | 2025-11-13 | $95.9M | Wellington Partners, Brandenburg Kapital, HBM Healthcare Investments +1 | 11 to 50 | 2013 |
| Tubulis | Tubulis generates antibody-drug conjugates with unique properties for solid tumor indications. | Biotech | Munich, Germany | Series C | $400.6M | 2025-10-15 | $616.9M | HTGF (High-Tech Gruenderfonds), Bayern Kapital, Seventure Partners +1 | 51 to 100 | 2012 |
| Cutiss | Cutiss is a life science company that produces regenerative medicine and engineers skin tissue. | Biotech | Zürich, Switzerland | Series C | $38.8M | 2025-09-10 | $94.6M | Innosuisse | 11 to 50 | 2017 |
| ENYO Pharma | ENYO Pharma is a biopharmaceutical company based in Lyon, France. | Biotech | Lyon, France | Series C | $7.0M | 2025-06-12 | $108.8M | Bpifrance, OrbiMed, Sofinnova Partners +2 | 11 to 50 | 2014 |
| ImmunOs Therapeutics | ImmunOs Therapeutics is a clinical-stage biotechnology company. | Biotech | Schlieren, Switzerland | Series C | $11.0M | 2024-09-17 | Lightspeed Venture Partners, Innosuisse, Mission BioCapital +1 | 11 to 50 | 2014 | |
| Asceneuron | Asceneuron develops therapeutics for orphan tauopathies and Alzheimer's disease. | Biotech | Lausanne, Switzerland | Series C | $100.0M | 2024-07-16 | OrbiMed, Novo Holdings, EQT Life Sciences +1 | 1 to 10 | 2012 | |
| Memo Therapeutics | Memo Therapeutics conducts biotechnology research in antibody discovery and immune repertoire analysis. | Biotech | Schlieren, Switzerland | Series C | $22.0M | 2024-05-07 | $108.8M | Verve Ventures, Kurma Partners, Pureos Bioventures +1 | 11 to 50 | 2012 |
| Genomics | Genomics plc works to bring genomic medicine into healthcare. | Biotech | Oxford, United Kingdom | Series C | $44.6M | 2024-01-08 | $135.4M | Innovate UK, IP Group, Oxford Science Enterprises +1 | 101 to 250 | 2014 |
| Apollo Therapeutics | Apollo Therapeutics develops medicines by translating medical research into biopharmaceutical portfolios. | Biotech | Cambridge, United Kingdom | Series C | $33.5M | 2024-01-02 | $397.9M | UCL Technology Fund, Patient Square Capital, Rock Springs Capital | 51 to 100 | 2016 |
| Labster | Labster offers virtual laboratory simulations built on mathematical algorithms for e-learning. | Biotech | Copenhagen, Denmark | Series C | $47.0M | 2022-04-04 | Andreessen Horowitz, GGV Capital, Balderton Capital +1 | 251 to 500 | 2011 | |
| NBE-Therapeutics | NBE-Therapeutics develops oncology treatments for cancer patients. | Biotech | Basel, Switzerland | Series C | $22.0M | 2020-01-10 | $65.7M | Novo Holdings, Boehringer Ingelheim Venture Fund, PPF Group | 11 to 50 | 2012 |
| dacadoo | dacadoo offers digital lifestyle solutions through mobile apps from its base in Switzerland. | Biotech | Zürich, Switzerland | Series C | $71.1M | 2019-12-13 | Samsung Ventures | 51 to 100 | 2010 | |
| Andrew Alliance | Andrew Alliance is a Swiss pioneer in robotics for the life sciences sector. | Artificial intelligence | Geneva, Switzerland | Series C | $14.0M | 2018-06-12 | Venture Kick, Omega Funds, Rancilio Cube Sicaf | 11 to 50 | 2011 | |
| Endosense | Endosense develops medical technology that improves the reproducibility of catheter ablation for cardiac arrhythmias. | Biotech | Geneva, Switzerland | Series C | $41.2M | 2013-11-27 | 3i Group, VI Partners, Andera Partners +2 | 51 to 100 | 2003 | |
| Viroblock | Viroblock is a Swiss company developing antiviral technology for air filtration products. | Biotech | Geneva, Switzerland | Series C | $4.5M | 2012-02-14 | $4.5M | StartAngels Network, BlueOcean Ventures | 1 to 10 | 2005 |
| GILUPI | GILUPI develops medical devices that isolate rare cells from circulating blood in vivo. | Biotech | Potsdam, Germany | Series C | $4.8M | 2011-01-13 | $4.8M | HTGF (High-Tech Gruenderfonds), KfW, Brandenburg Kapital +1 | 11 to 50 | 2005 |
| MTM Laboratories | MTM Laboratories manufactures in-vitro diagnostic tests for detecting and diagnosing cervical and other cancers early. | Biotech | Heidelberg, Germany | Series C | $9.7M | 2010-11-08 | $109.7M | Wellington Partners, LBBW VC, Gilde Healthcare +2 | 1,001 to 5,000 | 1999 |
| Synosia Therapeutics | Synosia Therapeutics develops and commercializes products for unmet needs in psychiatry and neurology. | Biotech | Basel, Switzerland | Series C | $30.0M | 2010-10-12 | $94.0M | Novo Holdings, Versant Ventures, 5AM Ventures +2 | 1 to 10 | 2006 |
| CMOSIS nv | CMOSIS nv designs and supplies standard and custom CMOS image sensors for professional, scientific, and industrial uses. | Biotech | Antwerp, Belgium | Series C | $4.2M | 2009-08-10 | Capital-E, Vinnof | 51 to 100 | 2007 | |
| Signature Diagnostics GmbH | Signature Diagnostics GmbH develops translational oncology and genomics tests for cancer care. | Biotech | Potsdam, Germany | Series C | $7.6M | 2008-08-12 | KfW, BFB Fruehphasenfonds, EVP Capital Management +1 | 1 to 10 | 2004 |
Table 1. Biotech startups that raised Series C in Europe: the 26 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 111.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Basecamp Research | Basecamp Research is a biotechnology company that uses AI and biological data to develop therapeutics. | Artificial intelligence | London, United Kingdom | Series C | $140.0M | 2026-09-23 | $219.9M | True Ventures, redalpine, Hummingbird Ventures +1 | 51 to 100 | 2019 |
| 2 | ADCendo | ADCendo develops antibody-drug conjugates to target cancers with high unmet medical needs. | Biotech | Copenhagen, Denmark | Series C | $75.0M | 2026-04-14 | $324.6M | RA Capital Management, Novo Holdings, Gilde Healthcare +2 | 51 to 100 | 2017 |
| 3 | Microbiotica | Microbiotica develops live bacterial microbiome therapeutics and associated biomarkers. | Biotech | Cambridge, United Kingdom | Series C | $47.9M | 2026-10-16 | $130.7M | Seventure Partners, IP Group, Cambridge Innovation Capital +1 | 11 to 50 | 2016 |
| 4 | Automata | Automata provides laboratory automation software and hardware to increase efficiency in scientific workflows. | Artificial intelligence | London, United Kingdom | Series C | $45.0M | 2026-06-25 | $144.8M | Octopus Ventures, Firstminute Capital, Hummingbird Ventures +1 | 101 to 250 | 2015 |
| 5 | Nuclera | Nuclera provides a protein prototyping system that makes proteins readily available to drug discovery researchers. | Biotech | Cambridge, United Kingdom | Series C | $12.0M | 2026-01-13 | $157.8M | Innovate UK, Verve Ventures, Amadeus Capital Partners +2 | 101 to 250 | 2013 |
| 6 | Brainomix | Brainomix creates AI-powered imaging biomarkers that support precision medicine treatment decisions. | Artificial intelligence | Oxford, United Kingdom | Series C | $6.5M | 2026-02-24 | $60.2M | Innovate UK, Parkwalk Advisors, Boehringer Ingelheim Venture Fund +1 | 51 to 100 | 2010 |
Table 2. Biotech startups that raised Series C in Europe: the 6 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | KfW | Government investment office | Frankfurt, Germany | 7 | 6% | ||
| 2 | HTGF (High-Tech Gruenderfonds) | Venture capital firm | Bonn, Germany | 5 | 5% | ||
| 3 | Novo Holdings | Corporate venture arm | Hellerup, Denmark | 4 | 4% | 1 | ADCendo |
| 4 | Innovate UK | Entrepreneurship program | Swindon, United Kingdom | 4 | 4% | 2 | Brainomix, Nuclera |
| 5 | Seventure Partners | Venture capital firm | Paris, France | 3 | 3% | 1 | Microbiotica |
| 6 | Brandenburg Kapital | Government investment office | Potsdam, Germany | 3 | 3% | ||
| 7 | Wellington Partners | Venture capital firm | Munich, Germany | 3 | 3% | ||
| 8 | HBM Healthcare Investments | Venture capital firm | Zug, Switzerland | 3 | 3% | ||
| 9 | Andera Partners | Private equity firm | Paris, France | 3 | 3% | ||
| 10 | IP Group | Venture capital firm | London, United Kingdom | 2 | 2% | 1 | Microbiotica |
| 11 | Hummingbird Ventures | Venture capital firm | Brussels, Belgium | 2 | 2% | 2 | Basecamp Research, Automata |
| 12 | Gilde Healthcare | Private equity firm | Utrecht, The Netherlands | 2 | 2% | 1 | ADCendo |
| 13 | RA Capital Management | Startup incubator | Boston, United States | 2 | 2% | 1 | ADCendo |
| 14 | Boehringer Ingelheim Venture Fund | Corporate venture arm | Ingelheim Am Rhein, Germany | 2 | 2% | 1 | Brainomix |
| 15 | Amadeus Capital Partners | Venture capital firm | Cambridge, United Kingdom | 2 | 2% | 1 | Nuclera |
Table 3. Biotech startups that raised Series C in Europe: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 93 | 84% | $6.6B |
| Software | 14 | 13% | $514.9M |
| Artificial intelligence | 6 | 5% | $424.9M |
| Hardware | 6 | 5% | $144.8M |
| Education | 2 | 2% | $81.2M |
| Fintech | 1 | 1% |
Table 4. Biotech startups that raised Series C in Europe by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series C | 111 | 100% | $25.0M |
Table 5. Biotech startups that raised Series C in Europe by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Countries
| Countries | Companies | Share |
|---|---|---|
| United Kingdom | 38 | 34% |
| Switzerland | 20 | 18% |
| Germany | 15 | 14% |
| France | 11 | 10% |
| Denmark | 5 | 5% |
| The Netherlands | 5 | 5% |
| Spain | 4 | 4% |
| Belgium | 4 | 4% |
| Ireland | 3 | 3% |
| Portugal | 1 | 1% |
| Hungary | 1 | 1% |
| Finland | 1 | 1% |
Table 6. Biotech startups that raised Series C in Europe by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| London | 10 | 9% |
| Cambridge | 8 | 7% |
| Oxford | 5 | 5% |
| Geneva | 4 | 4% |
| Copenhagen | 3 | 3% |
| Dublin | 3 | 3% |
| Schlieren | 3 | 3% |
| Munich | 2 | 2% |
| Zürich | 2 | 2% |
| Barcelona | 2 | 2% |
| Wädenswil | 2 | 2% |
| Glasgow | 2 | 2% |
Table 7. Biotech startups that raised Series C in Europe by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| October 2026 | 2 | 20% | $357.9M |
| September 2026 | 1 | 10% | $140.0M |
| July 2026 | 1 | 10% | $37.7M |
| June 2026 | 1 | 10% | $45.0M |
| April 2026 | 2 | 20% | $131.0M |
| March 2026 | 1 | 10% | $105.0M |
| February 2026 | 1 | 10% | $6.5M |
| January 2026 | 1 | 10% | $12.0M |
Table 8. Biotech startups that raised Series C in Europe: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 10 | 9% | $835.1M |
| 2025 | 8 | 7% | $754.0M |
| 2024 | 11 | 10% | $390.8M |
| 2023 | 4 | 4% | $246.3M |
| 2022 | 5 | 5% | $197.1M |
| 2021 | 7 | 6% | $248.0M |
Table 9. Biotech startups that raised Series C in Europe by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2015 to 2019 | 25 | 23% |
| 2010 to 2014 | 35 | 32% |
| Before 2010 | 51 | 46% |
Table 10. Biotech startups that raised Series C in Europe by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 15 | 14% |
| 11 to 50 | 63 | 57% |
| 51 to 100 | 21 | 19% |
| 101 to 250 | 8 | 7% |
| 251 to 500 | 2 | 2% |
| 1,001 to 5,000 | 2 | 2% |
Table 11. Biotech startups that raised Series C in Europe by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series C and its headquarters is in Europe. On 16 November 2026 that is 111 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 26 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 111 rows: 11 have no round amount, 0 no city and 38 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in Europe whose last round is Series C are on the list?
- 111, in the file dated 16 November 2026. 10 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 111 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.